NCT05124067View on ClinicalTrials.gov

Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

January 30, 2022

Study Completion Date

March 12, 2022

Conditions
Postoperative Nausea and VomitingPost Operative PainEmergence Delirium
Interventions
DRUG

Dexamethasone

patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)

DRUG

Ondansetron

patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)

DRUG

Dexmedetomidine

Patients will receive dexmedetomidine (0.3 μg/kg)

DRUG

normal Saline

patients will receive normal saline.

Trial Locations (1)

00000

Sharurah Armed Forces Hospital, Sharurah

All Listed Sponsors
lead

Tanta University

OTHER

NCT05124067 - Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children | Biotech Hunter | Biotech Hunter